trending Market Intelligence /marketintelligence/en/news-insights/trending/-9MP_Rk9vPm3bzlDFX_kMg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Novelion Therapeutics to dissolve Jan. 16

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Novelion Therapeutics to dissolve Jan. 16

Novelion Therapeutics Inc. said the company will shut down Jan. 16 after the Supreme Court of British Columbia granted the orders for voluntary liquidation.

Alvarez & Marsal Canada Inc. will be appointed as the liquidator on the date, and concurrently, Michael Price, executive vice president and CFO, will resign. Price is the company's sole executive officer.

In addition, Price and two other directors, Suzanne Bruhn and Stephen Sabba, will resign from the board of the Vancouver, British Columbia-based company.

After the effective date, the transfer agent of Novelion's common shares will discontinue recording share transfers.